At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 200 enrolled
Drug / intervention
Placebo +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Iota-Carrageenan Nasal Spray 1.2 g/l (0.12 Percent) (Bisolviral) Versus Placebo Nasal Spray in the Early Treatment of Common Cold
In Brief
A Phase 4 clinical trial evaluating Placebo and Iota-Carrageenan for Common Cold. Completed, enrolled 200 participants across 1 site.
Detailed Summary
The aim of this clinical trial is to investigate the effect of Iota-Carrageenan treatment on cold symptoms. The effect of treatment on the duration of the cold and the patients viral load plus cytokine level indicating the inflammatory response will be analyzed.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommon Cold
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartSep 2013
First PostedSep 2013
Primary CompletionMar 2014
TodayJul 2026
First PostedSep 17, 2013
Enrollment StartSep 1, 2013
Primary CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 12.8 years ago
Interventions
Placebodevice
Nasal spray saline
Iota-Carrageenandevice
Nasal spray containing 1.20 g/l Iota-Carrageenan in saline